NICE approval for restricted-use hypophosphatasia therapy

05:48 EDT 23 Sep 2016 | Pharmafile

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of Alexion Pharmaceutical’s Strensiq (asfotase alfa) for children with perinatal- and infantile-onset hypophosphatasia.

read more

Original Article: NICE approval for restricted-use hypophosphatasia therapy


More From BioPortfolio on "NICE approval for restricted-use hypophosphatasia therapy"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...